How pembrolizumab is changing triple-negative breast cancer treatment

Triple-negative breast cancer (TNBC) has long been one of the hardest forms of breast cancer to treat, but that’s changing fast. Unlike other breast cancer subtypes, TNBC cells lack three key receptors: estrogen (ER), progesterone (PR), and HER2. That absence matters enormously. Most targeted therapies work by binding to one of these receptors, so when all three are missing, those treatments simply don’t apply.

Triple-negative breast cancer (TNBC) represents a relatively small portion of all breast cancer diagnoses, though estimates of its prevalence vary across different populations and studies. TNBC is known for being more aggressive, with a higher risk of recurrence compared to other subtypes. For decades, that aggressive biology left oncologists with one primary tool: chemotherapy. Systemic and non-targeted by nature, chemo attacks rapidly dividing cells broadly, and while it can be effective, it doesn’t offer the precision that the biology of TNBC demands.

The shift came when researchers began looking at the immune system as a potential weapon. That pivot produced a meaningful breakthrough: pembrolizumab for TNBC became the first immunotherapy to receive broad FDA approval for this subtype, clearing a path that chemotherapy alone couldn’t. In 2021, the FDA approved pembrolizumab in combination with chemotherapy for high-risk early-stage TNBC, a landmark decision grounded in robust clinical evidence from the KEYNOTE-522 trial.

Understanding why pembrolizumab works, and how it interacts with the immune system to target tumor cells, starts with understanding what makes TNBC so immunologically distinct in the first place.

How pembrolizumab unmasks TNBC cells

Pembrolizumab is a checkpoint inhibitor that works by blocking the PD-1 pathway, essentially lifting a disguise that cancer cells use to avoid destruction by the immune system.

To understand why this matters for triple-negative breast cancer prognosis, it helps to know how cancer hides in the first place. Healthy cells carry proteins on their surface that signal to the immune system: “I belong here.” Cancer cells exploit this system by displaying a protein called PD-L1, which binds to a receptor called PD-1 on T-cells, the immune system’s primary attack force. When that binding happens, the T-cell essentially stands down. The tumor stays invisible, and it grows unchecked.

Pembrolizumab interrupts that handshake. By blocking the PD-1 receptor, it prevents cancer cells from sending the “don’t attack me” signal. By blocking the PD-1 pathway, pembrolizumab helps the immune system do what it was meant to do: detect and fight cancer cells. With that molecular disguise stripped away, T-cells can recognize the tumor for what it is and mount a targeted response.

What makes this particularly significant in TNBC is that these tumors tend to be more immunogenic, meaning they often generate a stronger immune reaction when the brakes are released. Research published in the National Library of Medicine confirms that TNBC has higher PD-L1 expression rates compared to other breast cancer subtypes, making it a strong candidate for this type of immunotherapy.

That biological compatibility is a big part of why the clinical results have been so striking, and why the timing of treatment turns out to be critical.

The KEYNOTE-522 breakthrough: why timing matters

The KEYNOTE-522 trial redefined when immunotherapy should be used, making timing central to improving the triple-negative breast cancer survival rate.

The trial structured treatment across two distinct phases. Neoadjuvant therapy is delivered before surgery, with the goal of shrinking the tumor and eliminating microscopic spread. Adjuvant therapy follows surgery, continuing treatment to reduce the risk of recurrence. KEYNOTE-522 tested pembrolizumab across both phases, which is what made its design, and its results, so significant.

Pathologic complete response (pCR) is the key benchmark here. pCR in early-stage TNBC is associated with a positive outlook and very low rates of recurrence, particularly in patients with more aggressive cancers like TNBC. In the KEYNOTE-522 trial, the pCR rate climbed to 64.8% with pembrolizumab added to chemotherapy, compared to 51.2% with chemotherapy alone, a clinically meaningful jump.

Beyond pCR, updated five-year follow-up data confirmed that the benefit holds over time. Patients who received pembrolizumab showed improved event-free survival compared to those on chemotherapy alone, showing that early immune engagement drives durable outcomes. Understanding who qualifies for this approach, and how PD-L1 status factors in, is where the next piece of the picture comes together.

Navigating the treatment protocol and eligibility

Not every patient with TNBC follows the same treatment path. Eligibility depends on disease stage, and in metastatic cases, on biomarker testing results.

For high-risk early-stage TNBC, the FDA approved pembrolizumab in combination with chemotherapy as neoadjuvant treatment, then continued as a single agent after surgery. Eligibility typically includes:

• Tumor size of T1c (≥1 cm) or higher, or node-positive disease
• Confirmed TNBC status on pathology
• No prior systemic treatment for this diagnosis
• Adequate organ function to tolerate combination chemotherapy

For high-risk early-stage TNBC, neoadjuvant chemotherapy may be combined with pembrolizumab to shrink large tumors before surgery, followed by additional pembrolizumab after surgery to help reduce the chances of cancer recurrence. This extended schedule is designed to keep the immune system engaged well beyond the operating room.

For metastatic TNBC, the pathway is different. Here, PD-L1 testing plays a decisive role. Pembrolizumab is indicated for patients whose tumors express PD-L1 with a combined positive score (CPS) ≥10, making biomarker testing an essential step before treatment decisions are made.

Genetic testing also matters. BRCA mutation status can influence sequencing decisions, as some patients may be candidates for PARP inhibitors alongside or following immunotherapy. Knowing your full molecular profile upfront gives your oncology team the clearest picture of which options apply to you.

It’s worth noting that this combination therapy carries a distinct side effect profile, one that’s important to understand before you start.

Managing immune-related side effects (irAEs)

One of the most important distinctions with immunotherapy for triple-negative breast cancer is that its side effects differ from those of traditional chemotherapy, and recognizing that difference early can make a real impact on outcomes.

Unlike chemo side effects, which stem from the drug attacking fast-dividing cells, irAEs occur when the immune system becomes overactivated and begins attacking healthy tissue. Immunotherapy can cause inflammation throughout the body that may affect multiple organs, such as the thyroid gland, liver, and kidneys, and in some cases these side effects can be debilitating. Immune-mediated adverse events may appear even after treatment has stopped, making ongoing vigilance essential.

Common irAEs include:

• Thyroid dysfunction, hypothyroidism or hyperthyroidism, often manageable with medication
• Skin reactions, rashes, itching, or inflammation
• Colitis, diarrhea or abdominal pain that can escalate quickly if left untreated
• Pneumonitis, hepatitis, and adrenal insufficiency, less common but potentially serious

The key principle: don’t wait to report symptoms. What feels like a minor rash or an upset stomach could signal a developing irAE that responds well to early intervention but worsens with delay. Immune side effects from pembrolizumab result from the immune system’s misdirected response toward normal tissues rather than direct drug toxicity, which means managing them requires different awareness and monitoring strategies.

Open, proactive communication with your oncology team is non-negotiable here. Keep a symptom log, report changes promptly, and ask your provider which symptoms warrant a same-day call. Understanding the full picture of treatment, including what to watch for after active therapy ends, sets the foundation for everything that follows.

The bottom line: what you need to know

Pembrolizumab plus chemotherapy is now the established standard of care for high-risk early-stage TNBC, and five-year follow-up data from KEYNOTE-522 confirms that this combination delivers a significant overall survival benefit.

Achieving pathological complete response (pCR), with no visible cancer remaining at surgery, is one of the strongest predictors of long-term recurrence-free survival. That’s why the treatment protocol is designed to maximize the chance of reaching pCR before the operating room. For patients with high-risk early TNBC, this is the recommended path supported by published clinical evidence and FDA approval.

Understanding pembrolizumab side effects in breast cancer is equally essential. As covered earlier, immune-related adverse events (irAEs), such as thyroid dysfunction, colitis, or pneumonitis, require their own monitoring plan. Patients who notice new or unusual symptoms between appointments shouldn’t wait; early reporting enables faster intervention and helps avoid treatment interruption.

Finally, accessing and sustaining these treatments depends on having organized, accessible medical records, including biomarker testing results, staging details, and a clear treatment timeline. Patients who arrive at appointments prepared tend to have more productive conversations with their oncologists and are better positioned to advocate for themselves.